NNNN is the ticker symbol for Anbio Biotechnology, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks NNNN with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is NNNN a good stock to buy?

NNNN is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/NNNN.

Where does 13F Pro source NNNN data?

All Anbio Biotechnology fundamentals and ownership data come directly from SEC EDGAR. Anbio Biotechnology files with the SEC under CIK 1982708. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Anbio Biotechnology(NNNN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Anbio Biotechnology (NNNN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. NNNN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $23.5m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), Anbio Biotechnology reports quarterly revenue of $8.6M, net income of $6.4M, an operating margin of 66.7%. Top institutional holders of NNNN by reported 13-F value include GEODE CAPITAL MANAGEMENT, BANK OF AMERICA, BNP PARIBAS FINANCIAL MARKETS, based on the most recent SEC filings. NNNN trades on the Nasdaq exchange and files with the SEC under CIK 1982708. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NNNN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anbio Biotechnology directly from SEC EDGAR.

Revenue

$8.6M

Net Income

$6.4M

Operating Margin

66.7%

NNNN key financials by period

Anbio Biotechnology reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2025	20-F	$8.6M	$6.4M	66.7%
FY 2024	20-F	$8.2M	$2.4M	24.4%
FY 2023	20-F	$6.7M	$2.3M	29.2%
FY 2022	20-F	$23.5M	$10.0M	43.3%

Institutions holding NNNN

Institutional investors reporting a position in Anbio Biotechnology on SEC Form 13F.
Institution	Shares	Value	Reported
GEODE CAPITAL MANAGEMENT	26,736	$366.6K	2026-06-30
BANK OF AMERICA	13,419	$184.0K	2026-06-30
BNP PARIBAS FINANCIAL MARKETS	11,800	$161.8K	2026-06-30
MARSHALL WACE, LLP	11,502	$157.7K	2026-06-30
MORGAN STANLEY	7,231	$99.1K	2026-06-30
UBS Group AG	828	$11.4K	2026-06-30
EverSource Wealth Advisors	187	$2.6K	2026-06-30
OSAIC	77	$1.1K	2026-06-30
JPMORGAN CHASE	53	$718.00	2026-06-30
Bare Financial Services	15	$206.00	2026-06-30

SEC EDGAR: CIK 1982708 →

Anbio Biotechnology

NNNN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $23.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.